Autologous tumor rejection in humans: Trimming the myths

Immunological Investigations

Volumn 35, Issue 3-4, 2006, Pages 437-458

  Wang, Ena ^a   Panelli, Monica ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Basal cell carcinoma; Epstein Barr virus; Immunization Immunotherapy interleukin 2 melanoma; Renal cell carcinoma

Indexed keywords

HLA ANTIGEN; INTERLEUKIN 2;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; BASAL CELL CARCINOMA; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; EXPERIMENTAL MODEL; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; KIDNEY CARCINOMA; PRIORITY JOURNAL; REVIEW; TARGET CELL; TISSUE SPECIFICITY; TUMOR REJECTION;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS; TUMOR ESCAPE;

EID: 33747600615     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130600762385     Document Type: Review

References (117)

1. Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., Little, S., Havlir, D. V., Richman, D. D., Gruener, N., Pape, G., Waters, A., Easterbrook, P., Salio, M., Cerundolo, V., McMichael, A., Rowland-Jones, S. L. (2002). Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8(4):379-385.
2. Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D. R., Hawkins, M., Paradise, C., Kunkel, L., Rosenberg, S. A. (1998). High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7):2105-2116.
3. Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., Brasnu, D. F., Tartour, E. (2006). Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12(2):465-472.
4. Boon, T., Coulie, P., Marchand, M., Weynants, P., Wolfel, T., Brichard, V. (1994). Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv. Oncol. 53-69.
5. Boon, T., Coulie, P. G., Van den Eynde, B. (1997). Tumor antigens recognized by T cells. Immunol. Today 18(6):267-268.
6. Brander, C., O'Connor, P., Suscovich, T., Jones, N. G., Lee, Y., Kedes, D., Ganem, D., Martin, J., Osmond, D., Southwood, S., Sette, A., Walker, B. D., Scadden, D. T. (2001). Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis, 184(2):119-126.
7. Champagne, P., Ogg, G. S., King, A., Knabenhans, C., Ellefsen, K., Nobile, M., Appay, V., Rizzardi, G. P., Fleury, S., Lipp, M., Forster, R., Rowland-Jones, S., Sekaly, R.-P., McMichael, A. J., Pantaleo, G. (2001). "Skewed maturation of memory HIV-specific CD8 T lymphoctes.", Nature 410:106-111.
8. Chua, D., Huang, J., Zheng, B., Lau, S. Y., Luk, W., Kwong, D. L., Sham, J. S., Moss, D., Yuen, K. Y., Im, S. W., Ng, M. H. (2001). Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. J. Cancer 94(1):73-80.
9. Conti, P., Kempuraj, D., Kandere, K., Di Gioacchino, M., Reale, M., Barbacane, R. C., Castellani, M. L., Mortari, U., Boucher, W., Letourneau, R., Theoharides, T. C. (2002). Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc. 23(2):103-108.
10. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., Marincola, F. M. (1997). Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J. Sci. Am. 3(1):37-44.
11. Cuenca, A., Cheng, F., Wang, H., Brayer, J., Horna, P., Gu, L., Bien, H., Borrello, I. M., Levitsky, H. I., Sotomayor, E. M. (2003). Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63(24):9007-9015.
12. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M. L., Knutson, K. L., Chen, L., Zou, W. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9):942-949.
13. Curtsinger, J. M., Johnson, C. M., Mescher, M. F. (2003) CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J. Immunol. 171(10):5165-5171.
14. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3(11):991-998.
15. Dunn, G. P., Old, L. J., Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
16. Ensoli, B., Sirianni, M. C. (1998). Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology. Crit. Rev. Oncog. 9(2):107-124.
17. Fuchs, E. J., Matzinger, P. (1996). "Is cancer dangerous to the immune system?", Semin. Immunol. 8(5):271-280.
18. Gottschalk, S., Heslop, H. E., Rooney, C. M. (2002). "Treatment of Epstein-Barr virus-associated malignancies with specific T cells.", Adv. Cancer Res. (84):175-201.
19. Green, M. (2001). Management of Epstein-Barr virus-induced post-tranplant lymphoproliferative disease in recipients of solid organ transplanation. Am. J. Transplant 1(2):103-108.
20. Hamann, D., Baars, P. A., Rep, M. H. G., Hoolbrink, B., Kerkhof-Garde, S. R., Klein, M. R., van Lier, R. A. W. (1997). "Phenotype and functional separation of memory and effector human CD8+ T cells.", J. Exper. Med. 186(9):1407-1418.
21. Haque, T., Taylor, C., Wilkie, G. M., Murad, P., Amlot, P. L., Beath, S., McKiernan, P. J., Crawford, D. H. (2001). Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 72(8):1399-1402.
22. Heslop, H. E., Rooney, C. M. (1997). Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev. 157:217-222.
23. Holmes, J., Hemmett, L., Garfield, S. 2005, The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur. J. Health Econ. 6(1):30-37.
24. Howell, W. M., Bateman, A. C., Turner, S. J., Collins, A., Theaker, J. M. (2002a). Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. (3):229-232.
25. Howell, W. M., Calder, P. C., Grimble, R. F. (2002b). Gene polymorphisms, inflammatory diseases and cancer. Proc. Nutr. Soc. 61(4):447-456.
26. Jin, P., Wang, E. (2003). Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J. Transl. Med. 1(8).
27. Kaech, S. M., Hemby, S., Kersh, E., Ahmed, R. (2002). Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111:837-851.
28. Kammula, U. S., Lee, K.-H., Riker, A., Wang, E., Ohnmacht, G. A., Rosenberg, S. A., Marincola, F. M. (1999). Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163:6867-6879.
29. Kast, W. M., Levitsky, H., Marincola, F. M. (2004). Synopsis of the 6th Walker's Cay Colloquium on cancer vaccines and immunotherapy. J. Transl. Med. 2(1):20.
30. Khanna, R., Bell, S., Sherritt, M., Galbraith, A., Burrows, S. R., Rafter, L., Clarke, B., Slaughter, R., Falk, M. C., Douglass, J., Williams, T., Elliott, S. L., Moss, D. J. (1999). Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 96(18):10391-10396.
31. Khong, H. T., Restifo, N. P. (2002). Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nature Immunol. 3(11):999-1005.
32. Kim, C. J., Parkinson, D. R., Marincola, F. M. (1997). Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J. Immunother. 21(1):1-16.
33. Korn, E. L., Troendle, J. F., McShane, L. M., Simon, R. (2003). Controlling the number of false discoveries: application to high-dimensional genomic data. J. Stat. Plan. Infer. 124(2):379-398.
34. Kreimer, A. R., Clifford, G. M., Boyle, P., Franceschi, S. (2005). Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev. 14(2):467-475.
35. Lally, K. M., Mocellin, S., Ohnmacht, G. A., Nielsen, M.-B., Bettinotti, M., Panelli, M. C., Monsurro', V., Marincola, F. M. (2001). Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer 93:841-847.
36. Lang, K. S., Recher, M., Junt, T., Navarini, A. A., Harris, N. L., Freigang, S., Odermatt, B., Conrad, C., Ittner, L. M., Bauer, S., Luther, S. A., Uematsu, S., Akira, S., Hengartner, H., Zinkernagel, R. M. (2005). Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11(2):138-145.
37. Leach, D. R., Krummel, M. F., Allison, J. P. (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-1736.
38. Lee, J. E., Reveille, J. D., Ross, M. I., Platsoucas, C. D. (1994). HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int. J. Cancer 59(4):510-513.
39. Lee, K.-H., Wang, E., Nielsen, M.-B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S. M., Rosenberg, S. A., Marincola, F. M. (1999a). Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163:6292-6300.
40. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., Davis, M. M. (1999b). Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5(6):677-685.
41. Lengauer, C., Kinzler, K. W., Vogelstein, B. (1998). "Genetic instabilities in human cancers.", Nature 396(6712):643-649.
42. Liu, D., O'Day, S. J., Yang, D., Boasberg, P., Milford, R., Kristedja, T., Groshen, S., Weber, J. (2005). Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin. Cancer Res. 11(3):1237-1246.
43. Malyguine, A., Strobl, S., Shafer-Weaver, K., Ulderich, T., Troke, A., Baseler, M., Kwak, L., Neelapu, S. (2004). A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J. Transl. Med. 2(1):9.
44. Marincola, F. M. (1994). Interleukin-2. Biol. Ther. Cancer Updates 4(3):1-16.
45. Marincola, F. M. (2005). A balanced review of the status of T cell-based therapy against cancer. J. Transl. Med. 3(1):16.
46. Marincola, F. M. Ferrone, S. (2003). Immunotherapy of melanoma: the good news, the bad news and what to do next. Sem. Cancer Biol. 13(6):387-389.
47. Marincola, F. M., Jaffe, E. M., Hicklin, D. J., Ferrone, S. (2000). Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:181-273.
48. Marincola, F. M., Rivoltini, L., Salgaller, M. L., Player, M., Rosenberg, S. A. (1996a). Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J. Immunother. 19(4):266-277.
49. Marincola, F. M., Shamamian, P., Rivoltini, L., Salgaller, M. L., Reid, J., Restifo, N. P., Simonis, T. B., Venzon, D., White, D. E., Parkinson, D. R. (1996b). HLA associations in the anti-tumor response against malignant melanoma. J. Immunother. 18:242-252.
50. Marincola, F. M., Wang, E., Herlyn, M., Seliger, B., Ferrone, S. (2003). Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol. 24(6):334-341.
51. Masramon, L., Ribas, M., Cifuentes, P., Arribas, R., Garcia, F., Egozcue, J., Peinado, M. A., Miro, R. (2000). Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. Cancer Genet Cytogenet. 121(1):17-21.
52. Matzinger, P. (1998). An innate sense of danger. Semin. Immunol. 10(5):399-415.
53. Matzinger, P. (2001). Danger model of immunity. Scand. J. Immunol. 54(1-2):2-3.
54. McKee, M. D., Roszkowski, J. J., Nishimura, M. I. (2005). T cell avidity and tumor recognition: implications and therapeutic strategies. J. Transl. Med. 3:35.
55. Migueles, S. A., Laborico, A. C., Shupert, W. L., Sabbaghian, M. S., Rabin, R., Hallahan, C. W., van Baarle, D., Kostense, S., Miedema, F., McLaughin, M., Ehler, L., Liu, S., Connors, M. (2002). HIV-specific CD8+ T cell proliferation is coupled to perforing expression and is maintained in nonprogressors. Nature Immunol. 3(11):1061-1068.
56. Minev, B. R. (2002). Melanoma vaccines. Semin. Oncol. 29(5):479-493.
57. Monsurro', V., Nagorsen, D., Wang, E., Provenzano, M., Dudley, M. E., Rosenberg, S. A., Marincola, F. M. (2002). Functional heterogeneity of vaccine-induced CD8+ T cells. J. Immunol. 168(11):5933-5942.
58. Monsurro', V., Nielsen, M.-B., Perez-Diez, A., Dudley, M. E., Wang, E., Rosenberg, S. A., Marincola, F. M. (2001). Kinetics of TCR use in response to repeated epitope-specific immunization. J. Immunol. 166:5817-5825.
59. Monsurro', V., Wang, E., Panelli, M. C., Nagorsen, D., Jin, P., Smith, K., Ngalame, Y., Even, J., Marincola, F. M. (2003). Active-specific immunization against cancer: is the problem at the receiving end? Sem. Cancer Biol. 13:473-480.
60. Monsurro', V., Wang, E., Yamano, Y., Migueles, S. A., Panelli, M. C., Smith, K., Nagorsen, D., Connors, M., Jacobson, S., Marincola, F. M. (2004). Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 104(7):1970-1978.
61. Moss, P., Khan, N. (2004). CD8(+) T-cell immunity to cytomegalovirus. Hum. Immunol. 65(5):456-464.
62. Nagorsen, D., Wang, E., Monsurro', V., Zanovello, P., Marincola, F. M., Panelli, M. C. (2005). Polarized monocyte response to cytokine stimulation. Genome Biol. 6:R15.
63. Neidhardt-Berard, E. M., Berard, F., Banchereau, J., Palucka, A. K. (2004). Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res. 6(4):R322-R328.
64. Nicol, A. F., Fernandes, A. T., Bonecini-Almeida, M. G. (2005). Immune response in cervical dysplasia induced by human papillomavirus: the influence of human immunodeficiency virus-1 co-infection-review. Mem. Inst Oswaldo Cruz 100(1):1-12.
65. Nielsen, M.-B., Monsurro', V., Miguelse, S., Wang, E., Perez-Diez, A., Lee, K.-H., Kammula, U. S., Rosenberg, S. A., Marincola, F. M. (2000). Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol. 165(4):2287-2296.
66. Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., Zinkernagel, R. M. (1999). Immune suerveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96:2233-2238.
67. Ohnmacht, G. A., Wang, E., Mocellin, S., Abati, A., Filie, A., Fetsch, P. A., Riker, A., Kammula, U. S., Rosenberg, S. A., Marincola, F. M. (2001). Short term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167:1809-1820.
68. Old, L. J., Chen, Y. T. (1998). New paths in human cancer serology. J. Exp. Med. 187(8):1163-1167.
69. Paczesny, S., Ueno, H., Fay, J., Banchereau, J., Palucka, A. K. (2003). Dendritic cells as vectors for immunotherapy of cancer. Sem. Cancer Biol. 13(6):439-447.
70. Panelli, M. C., Martin, B., Nagorsen, D., Wang, E., Smith, K., Monsurro', V., Marincola, F. M. (2003). A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 177(3):124-131.
71. Panelli, M. C., Riker, A., Kammula, U. S., Lee, K.-H., Wang, E., Rosenberg, S. A., Marincola, F. M. (2000). Expansion of Tumor/T cell pairs from Fine Needle Aspirates (FNA) of Melanoma Metastases. J. Immunol. 164(1):495-504.
72. Panelli, M. C., Wang, E., Phan, G., Puhlman, M., Miller, L., Ohnmacht, G. A., Klein, H., Marincola, F. M. (2002). Genetic profiling of peripheral mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol. 3(7):RESEARCH0035.
73. Panelli, M. C., White, R. L. Jr., Foster, M., Martin, B., Wang, E., Smith, K., Marincola, F. M. (2004). Forecasting the cytokine storm following systemic interleukin-2 administration. J. Transl. Med. 2:17.
74. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., Anichini, A. (2002). Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94(11):805-818.
75. Parmiani, G., Castelli, C., Rivoltini, L., Casati, C., Tully, G. A., Novellino, L., Patuzzo, A., Tosi, D., Anichini, A., Santinami, M. (2003). Immunotherapy of melanoma. Sem. Cancer Biol. 13(6):391-400.
76. Perez-Diez, A., Spiess, P. J., Restifo, N. P., Matzinger, P., Marincola, F. M. (2002). Intensity of the vaccine-elicited immune response determines tumor clearance. J. Immunol. 168:338-347.
77. Phan, G. Q., Touloukian, C. E., Yang, J. C., Restifo, N. P., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Seipp, C. A., Freezer, L. J., Morton, K. E., Mavroukakis, S. A., White, D. E., Rosenberg, S. A. (2003). Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. 26(4):349-356.
78. Pittet, M. J., Speiser, D. E., Lienard, D., Valmori, D., Guillaume, P., Dutoit, V., Rimoldi, D., Lejeune, F., Cerottini, J. C., Romero, P. (2001a). Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin. Cancer Res. 7(3):796s-803s.
79. Pittet, M. J., Speiser, D. E., Valmori, D., Rimoldi, D., Lienard, D., Lejeune, F., Cerottini, J.-C., Romero, P. (2001b). Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int. Immunopharmacol. 1(7):1235-1247.
80. Pittet, M. J., Zippelius, A., Speiser, D. E., Assenmacher, M., Guillaume, P., Valmori, D., Lienard, D., Lejune, F., Cerottini, J.-C., Romero, P. (2001c). Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J. Immunol. 166:7634-7640.
81. Pockaj, B. A., Sherry, R. M., Wei, J. P., Yannelli, J. R., Carter, C. S., Leitman, S. F., Carasquillo, J. A., Steinberg, S. M., Rosenberg, S. A., Yang, J. C. (1994). Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73:1731-1737.
82. Rinaldo, C. R., Jr., Torpey, D. J., III (1993). Cell-mediated immunity and immunosuppression in herpes simplex virus infection. Immunodeficiency 5(1):33-90.
83. Rooney, C. M., Roskrow, M. A., Smith, C. A., Brenner, M. K., Heslop, H. E. (1998). Immunotherapy of Epstein-Barr virus-associated cancer. J. Natl. Cancer Instit. Monogr. 23:89-93.
84. Rosenberg, S. A. (1997). Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18(4):175-182.
85. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A., White, D. E. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210:474-484.
86. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dufour, E., Schwartzberg, L., Spiess, P., Wunderlich, J., Parkhurst, M. R., Kawakami, Y., Seipp, C., Einhorn, J. H., White, D. (1998). Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4(3):321-327.
87. Rubin, J. T., Adams, S. D., Simonis, T., Lotze, M. T. (1991). HLA polymorphism and response to IL-2 bases therapy in patients with melanoma. Society for Biological Therapy 1991 Annual Meeting 1:18.
88. Rubio, V., Stuge, T. B., Singh, N., Betts, M. R., Weber, J. S., Roederer, M., Lee, P. P. (2003). Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9(11):1377-1382.
89. Sallusto, F., Lenig, D., Forster, R., Lipp, M., Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):659-660.
90. Sarwal, M., Chua, M. S., Kambham, N., Hsieh, S. C., Satterwhite, T., Masek, M., Salvatierra, O., Jr. (2003). Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 349(2):125-138.
91. Scheibenbogen, C., Letsch, A., Schmittel, A., Asemissen, A. M., Thiel, E., Keilholz, U. (2003). Rational peptide-based tumor vaccine development and T cell monitoring. Sem. Cancer Biol. 13(6):423-429.
92. Shafer-Weaver, K., Sayers, T., Strobl, S., Derby, E., Ulderich, T., Baseler, M., Malyguine, A. (2003). The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J. Transl. Med. 1(1):14.
93. Slingluff, C. L., Jr., Petroni, G. R., Yamshchikov, G. V., Hibbitts, S., Grosh, W. W., Chianese-Bullock, K. A., Bissonette, E. A., Barnd, D. L., Deacon, D. H., Patterson, J. W., Parekh, J., Neese, P. Y., Woodson, E. M., Wiernasz, C. J., Merrill, P. (2004). Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22(22):4474-4485.
94. Slingluff, C. L., Jr., Speiser, D. E. (2005). Progress and controversies in developing cancer vaccines. J. Transl. Med. 3:18.
95. Somasundaram, R., Caputo, L., Guerry, D., Herlyn, D. (2005). CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma. J. Transl. Med. 3:41.
96. Speiser, D. E., Colonna, M., Ayyoub, M., Cella, M., Pittet, M. J., Batard, P., Valmori, D., Guillaume, P., Lienard, D., Cerottini, J. C., Romero, P. (2001). The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J. Immunol. 167(11):6165-6170.
97. Speiser, D. E., Pittet, M. J., Rimoldi, D., Guillame, P., Luescher, I. F., Lienard, D., Lejeune, F., Cerottini, J.-C., Romero, P. (2003a). Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor specific T cells. Sem Cancer Biol, 13(6):461-472.
98. Speiser, D. E., Pittet, M. J., Rimoldi, D., Guillaume, P., Luescher, I. F., Lienard, D., Lejeune, F., Cerottini, J. C., Romero, P. (2003b). Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol. 13(6):461-472.
99. Straathof, K. C., Bollard, C. M., Popat, U., Huls, M. H., Lopez, T., Morriss, M. C., Gresik, M. V., Gee, A. P., Russell, H. V., Brenner, M. K., Rooney, C. M., Heslop, H. E. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105(5):1898-1904.
100. Stroncek, D. F., Basil, C., Nagorsen, D., Deola, S., Arico, E., Smith, K., Wang, E., Marincola, F. M., Panelli, M. C. (2005). Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J. Transl. Med. 3(1):24.
101. Talebi, T., Weber, J. S. (2003). Peptide vaccine trials for melanoma: preclinical background and clinical results. Sem. Cancer Biol. 13(6):431-438.
102. Terabe, M., Berzofsky, J. A. (2004). Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16(2):157-162.
103. Thor Straten, P., Schrama, D. D., Andersen, M. H., Becker, J. C. (2004). T cell clonotypes in cancer. J. Transl. Med. 2(1):11.
104. Tomaru, U., Yamano, Y., Nagai, M., Maric, D., Kaumaya, P. T., Biddison, W., Jacobson, S. (2003). Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat. Med. 9(4):469-476.
105. Trofe, J., Beebe, T. M., Buell, J. F., Hanaway, M. J., First, M. R., Alloway, R. R., Gross, T. G., Woodle, E. S. (2004). Posttransplant malignancy. Prog. Transplant 14(3):193-200.
106. Urosevic, M., Maier, T., Benninghoff, B., Slade, H., Burg, G., Dummer, R. (2003). Mechanisms unerlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch. Dermatol. 139(10):1325-1332.
107. van Baarle, D., Kostense, S., van Oers, M. H. J., Miedema, F. (2002). Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol. 23(12):586-591.
108. Viguier, M., Lemaitre, F., Verola, O., Cho, M. S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., Ferradini, L. (2004). Foxp3 expressing CD4 + CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173(2):1444-1453.
109. Wang, E., Miller, L. D., Ohnmacht, G. A., Mocellin, S., Petersen, D., Zhao, Y., Simon, R., Powell, J. I., Asaki, E., Alexander, H. R., Duray, P. H., Herlyn, M., Restifo, N. P., Liu, E. T., Rosenberg, S. A., Marincola, F. M. (2002). Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62:3581-3586.
110. Wang, E., Marincola, F. M., Stroncek, D. (2005). Human leukocyte antigen (HLA) and Human Neutrophil Antigen (HNA) systems. In Hoffman, R., Hematology: Basic Principles and Practice., 4th edn, R. Hoffman et al., eds., Elsevier Science, Philadelphia, PA, pp. 2401-2432.
111. Wang, E., Panelli, M. C., Zavaglia, K., Mandruzzato, S., Hu, N., Taylor, P. R., Seliger, B., Zanovello, P., Freedman, R. S., Marincola, F. M. (2004). Melanoma-restricted genes. J. Transl. Med. 2:34.
112. Wherry, E. J., Teichgraber, V., Becker, T. C., Masopust, D., Kaech, S. M., Antia, R., von Andrian, U. H., Ahmed, R. (2003). Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol. 4(3):225-234.
113. Wolfel, T., Klehmann, E., Muller, C., Schutt, K. H., Meyer zum Buschenfelde, K. H., Knuth, A. (1989). Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exper. Med. 170:797-810.
114. Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., June, C. H. (2002). Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168(9):4272-4276.
115. Yamaguchi, T., Sakaguchi, S. (2005) Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol.
116. Yee, C. (2005). Adoptive T cell therapy: addressing challenges in cancer immunotherapy. J. Transl. Med. 3:17.
117. Zea, A. H., Curti, B. D., Longo, D. L., Alvord, W. G., Strobl, S. L., Mizoguchi, H., Creekmore, S. P., O'Shea, J. J., Powers, G. C., Urba, W. J., Ochoa, A. C. (1995). Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1:1327-1335.